Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study

• Published in: Nutrients Vol. 11; no. 11; p. 2580
• Main Authors: Castellino, Giuseppa, Nikolic, Dragana, Magán-Fernández, Antonio, Malfa, Giuseppe Antonio, Chianetta, Roberta, Patti, Angelo M., Amato, Antonella, Montalto, Giuseppe, Toth, Peter P., Banach, Maciej, Cicero, Arrigo F. G., Rizzo, Manfredi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.10.2019; MDPI
• Subjects: blood lipids; body weight; chlorogenic acid; Cytokines; Diabetes; Disease prevention; Double-blind studies; Enzymes; Fatty liver; Functional foods & nutraceuticals; Gastroenterology; Lipids; Liver diseases; luteolin; men; Metabolic syndrome; nutrition risk assessment; Obesity; Oxidative stress; placebos; Plasma; Substance abuse treatment; transaminases; ultrasonography; waist circumference; women; Womens health; United States > US; Italy; metabolic syndrome; non-alcoholic fatty liver disease; type 2; cynara; dietary supplements; diabetes mellitus; cardiovascular diseases

The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-contro...